Cambridge Healthtech Institute’s 5th Annual
SYMPOSIUM: RNA and LNP Production and Formulation
Scaling and Delivering RNA Medicines Using High-Quality, Stable Lipid Nanoparticles
August 10, 2026
Cambridge Healthtech Institute’s 4th Annual RNA and LNP Production and Formulation meeting delves into the CMC, analytical, and manufacturing advances shaping RNA therapeutics and lipid nanoparticle-based delivery. The program explores innovations in analytical and process technologies for mRNA/LNPs, including dsRNA characterization, process control, and novel methods for LNP measurement and stability. Strong emphasis is placed on scalable RNA production, novel proceess, continuous and automated manufacturing, impurity control, and streamlined purification to enable commercial readiness. The agenda also highlights next-generation targeted mRNA-LNP technologies, digitalized workflows, and formulation innovations that enhance stability, optimize lipid composition, and improve delivery performance.
Coverage will include, but is not limited to:
- CMC, Standards, and Raw Materials
- Phase appropriate strategies for early-stage development, setting CQAs
- Raw material management and qualification
- Defining and implementing FDA’s platform technology designation
- Quality Attributes, quality control, reducing variability, screening strategies
- Impurities, Analytics, And Quality
- Quality of materials for RNA-Based Products
- Impurities—process controls, ensuring quality
- Detection and removal of dsRNA
- Online analytics: In process, CQAs
- Release testing strategies for RNA and DNA therapies
- Synthesis, Scale Up, and Purification
- Scaling up mRNA and RNA to kg production
- Optimizing scale up—continuous flow process, automation
- Continuous processing for mRNA and RNA
- Purification strategies: Simplifying purification at scale
- Preparing for commercial manufacturing
- Lipid Nanoparticle Production/ Target Delivery of mRNA
- Target delivery of mRNA
- Improving manufacture of mRNA–LNPs: linking early to large-scale manufacturing
- Next-gen payloads and non-viral delivery
- Application of LNPs in in vivo programs
- Analytical frameworks and CQAs
- Emphasis on digitalization to support productivity, efficiency, and data-driven decision-making
- Lipid Nanoparticle Stability and Formulation
- Enhancing mRNA–LNP Stability: Formulation and Storage Innovations
- Formulation design Considerations: lipid composition, particle size, and encapsulation efficiency
- Target delivery of mRNA
- Novel innovations in LNP
The deadline for priority consideration is January 23, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: